TD Asset Management’s Epizyme, Inc EPZM Stock Holding History

TD Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-45,374	Closed	-$395K	–	1610
2021 Q1	$395K	Hold	45,374	–	–	﹤0.01%	1430
2020 Q4	$493K	Hold	45,374	–	–	﹤0.01%	1334
2020 Q3	$541K	Hold	45,374	–	–	﹤0.01%	1221
2020 Q2	$729K	Hold	45,374	–	–	﹤0.01%	1134
2020 Q1	$704K	Buy	45,374 +12,900	+40%	+$277K	﹤0.01%	1091
2019 Q4	$799K	Buy	+32,474	New	+$482K	﹤0.01%	1148
2019 Q3	–	Sell	-21,394	Closed	-$268K	–	1377
2019 Q2	$268K	Buy	21,394 +1,400	+7%	+$18K	﹤0.01%	1265
2019 Q1	$248K	Buy	+19,994	New	+$224K	﹤0.01%	1284
2018 Q1	–	Sell	-14,600	Closed	-$183K	–	1379
2017 Q4	$183K	Buy	+14,600	New	+$212K	﹤0.01%	1307
2014 Q4	–	Sell	-15,400	Closed	-$417K	–	1401
2014 Q3	$417K	Sell	15,400 -5,300	-26%	-$165K	﹤0.01%	1076
2014 Q2	$644K	Buy	+20,700	New	+$487K	﹤0.01%	976

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TD Asset Management's EPZM Position: Q2 2021 in Review

TD Asset Management sold out of Epizyme, Inc (EPZM) in Q2 2021, closing a stake of 45,374 shares — an estimated $395K sold.

TD Asset Management first reported a position in EPZM in Q2 2014 and held it in 11 quarters. The position peaked at $799K in Q4 2019. 127 funds tracked by Wall St. Rank hold EPZM as of Q2 2021.

TD Asset Management reported no remaining Epizyme, Inc position as of Q2 2021 after selling out during the quarter.
TD Asset Management sold 45,374 Epizyme, Inc shares in Q2 2021, an estimated $395K.
TD Asset Management first reported a position in Epizyme, Inc in Q2 2014 and held it in 11 quarters.
TD Asset Management's Epizyme, Inc position peaked at $799K in Q4 2019.
127 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2021.

Based on TD Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.